Status:
WITHDRAWN
A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period
Lead Sponsor:
United States Naval Medical Center, Portsmouth
Conditions:
Contraception
Postpartum Period
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The primary objective of the investigators study is to determine if there is a difference in continuation rates at six months in women who are randomized to have the Levonorgestrel Intrauterine System...
Detailed Description
The control arm of our study will be women who are randomized to receive LNG-IUS in the Interval time period. The study arm will consist of women randomized to receiving Immediate placement. The inve...
Eligibility Criteria
Inclusion
- All women \>37 weeks gestation who desire LNG-IUS for postpartum contraception who do not have a contraindication as described below will be offered participation in our study.
Exclusion
- Contraindications to the LNG-IUS include:
- Pregnancy or suspicion of pregnancy
- Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
- Postpartum endometritis within the past 3 months
- Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear
- untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections
- acute liver disease or liver tumor
- hypersensitivity to any component of the product
- known or suspected carcinoma of the breast
- Any of these conditions would exclude the patient from receiving these forms of contraception in our study.
- In addition the following intrapartum findings, the following would exclude the patient:
- Delivery \<37 weeks
- Intrapartum chorioamnionitis (defined as maternal fever \>100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid
- Postpartum Hemorrhage (defined as \>500cc EBL for spontaneous vaginal delivery or \>1000cc for cesarean delivery)
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 28 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01161095
Start Date
July 1 2010
End Date
May 28 2014
Last Update
July 20 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for the Medical Sciences
Little Rock, Arkansas, United States, 72205
2
Naval Medical Center
Portsmouth, Virginia, United States, 23507